The U.S. Food and Drug Administration has granted approval for a generic version of allopurinol, submitted under ANDA 077353. The product is manufactured by Chartwell RX, LLC and will be marketed as prescription tablets.
The approved dosage forms are oral tablets containing 100 mg and 300 mg of allopurinol. Both strengths are listed under the brand name “ALLOPURINOL” with product numbers 001 and 002. The FDA submission history includes an original approval on September 8 2005 and labeling supplements filed on March 19 2019 and March 19 2025.
Cập nhật pháp chế25 thg 9, 2026•1 phút đọc
FDA Approves Chartwell Allopurinol Generic (ANDA077353)
FDA has approved Chartwell RX's generic allopurinol tablets (100 mg and 300 mg) under ANDA 077353, confirming prescription status and labeling updates.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: FDA.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá